Submit a Comment

Melanoma and Other Skin Cancers: Immediate Impact of 2016 ASCO Presentations on Clinical Practice

Introduction

In an effort to provide you with timely market feedback from the 2016 ASCO Annual Meeting, OBR and MDoutlook are pleased to share results from MDoutlook’s OncoPolls™ conducted immediately after the meeting. This report explores skin cancer (melanoma and merkel cell carcinoma) presentations concerning the use of checkpoint inhibitors and the combination of BRAF and MEK inhibitors.

OncoPoll™ Methodology

  • Primary research phase involved a global survey to verified and validated medical oncologists and multi-disciplinary physicians with an identified clinical interest in genitourinary cancers utilizing targeting parameters within the proprietary MDoutlook® global cancer treater panel
  • Timing: June 2016. Launched 1 day after close of 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago, IL, June 3-7, 2016
  • Fielding to proprietary panel of cancer treaters, targeted by clinical interest
  • Data capture via interactive web-based survey instrument, utilizing proven MDoutlook methodology and proprietary technology
  • Links to discussed abstracts on the ASCO website were provided within the survey
  • Reponses at data collection: 90
  • Responses are from 14 countries: Austria, Belgium, Brazil, Canada, France, Germany, Hungary, Italy, Romania, Spain, Sweden, Switzerland, United Kingdom and US

OncoPoll_Melanoma_Figure1

 

OncoPoll_Melanoma_Figure2

 

OncoPoll_Melanoma_Figure3

Key Conclusions

  • On a 0 – 5 scale of 0 = no awareness to 5 = very aware, clinicians have an above average awareness of these presentations
    • A slightly higher level of awareness is seen by those outside of the US
    • Attendees of the conference showed a higher level of awareness (not shown)
    • The awareness about avelumab in merkel cell carcinoma was somewhat lacking compared to the other antibodies in melanoma
  • Clinical impact, also rated on a 0 – 5 scale of 0 = no impact at all to 5 = very important, for these agents in general are seen as very clinically meaningful
    • US oncologists rate the merkel cell abstract as less clinically important
    • For most of these abstracts, importance assigned is slightly higher by those who did not attend the meeting, although the differences are never very large

OncoPoll_Melanoma_Figure4

Key Conclusions

  • On the same 0 – 5 scale, there is an above average level awareness about this presentation outside of the US, while awareness in the US is slightly lower
    • Higher level of awareness among the attendees compared to those who did not attend (not shown)
  • Oncologists view this as an important presentation, with those outside the US rating it as very clinically important
    • Attendance at the meeting does not impact the rating of clinical importance (not shown)
  • Oncologists view this as an important presentation, with those outside the US rating it as very clinically important
    • Attendance at the meeting does not impact the rating of clinical importance (not shown)
    • Even with the clinical importance of this abstract, expected usage of the BRAF + MEK inhibitor combination as 1st line therapy for BRAF V600E/K-mutant melanoma is expected to loose favor to the use of checkpoint inhibitors (not shown)

Conclusions: Immediate Impact of 2016 ASCO Presentations on Clinical Practice for Melanoma and Merkel Cell Carcinoma

  • All of these studies highlight the importance of the ASCO Annual Meeting to the entire global oncology community – awareness of these presentations are high and can occur quite quickly even for those who did not attend
  • The importance of these presentations suggest that integration of these results into clinical practice will happen in relatively short order, especially since most of these agents are already widely available and in use

For a more detailed analysis report, please click here to download the full report.

Submitted by Robert Stephan, VP, Research and Physician Society, and Jan Heybroek, President MDoutlook.

 

You must be logged in to post a comment